PositiveID Corporation (fka PSID)

[greaseyfingers]

Highlights for first half of 2012

Successfully tested M-BAND, recently featured in Bloomberg Businessweek, to detect five organisms on the CDC's Select Agents list, a requirement for BioWatch

Added chief technology advisor and biodefense expert, Dr. Kimothy Smith

Collaborated with the University of Nevada to produce irradiated samples for the development of a biodosimetry cartridge for measuring radiation exposure

Awarded U.S. Patent for first-of-its-kind Dragonfly detection system for molecular biological diagnostics. Dragonfly is the Company's system that uses disposable microfluidic cartridges for biological sample processing and detection

Partnered with the Diabetes Research Institute at the University of Miami and Schneider Children's Medical Center of Israel to support the development of the Company's diabetes management products, including Easy Check(TM) and GlucoChip(TM)

Commenced clinical study of PositiveID's Easy Check, a non-invasive breath glucose detection device, at Schneider Children's Medical Center of Israel under the leadership of world-renowned endocrinologist Prof. Moshe Phillip

Won gold award at Connected World Value Chain Awards for its iglucose system for diabetes management
Goals for second half of 2012:

Enter into strategic partnerships and/or teaming agreements with large government contractors for M-BAND manufacturing and system integration for BioWatch Gen-3

Submit proposal upon release of the final BioWatch Gen 3 RFP, currently scheduled for release in the fourth quarter of calendar 2012, from Department of Homeland Security for the $3.1 billion BioWatch Gen-3 procurement

Commence second stage of Easy Check clinical study at Schneider Children's Medical Center in Israel

Complete bench-top unit of GlucoChip glucose-sensor and initiate strategic partnerships

Continue development of Dragonfly Rapid MDx Cartridge-based diagnostic system for point-of-care diagnostics

Complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization

Complete strategic financing to capitalize the Company to execute on these opportunities

William J. Caragol, Chairman and CEO of PositiveID, stated, "We continue to focus on our molecular diagnostic business and are excited about the significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of our innovative Dragonfly system. We are very proud of our accomplishments year to date and will continue to execute our plan, described above. We believe that we are well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products. That progress, in conjunction with a strategic financing to fully capitalize the Company, we believe, will allow us to unlock value for stockholders."

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing.

Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

For more information on PositiveID, please visit http://www.PositiveIDCorp.com.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79489442